Invivyd, Inc.

    Jurisdiction
    United States
    ISIN
    US00534A1025 (IVVD)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Read full profile

    Fundamentals

    Net revenue
    €2.56
    Gross margin
    100.0%
    EBIT
    -€300.32M
    EBIT margin
    -11,736,520,833.3%
    Net income
    -€248.84M
    Net margin
    -9,724,600,000.0%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Allen Robert D. III Chief Scientific Officer -46K $0.60 -$27.56K
    Andersen Jill Chief Legal Officer, Secretary -83K $0.60 -$49.65K
    Duke William E. Chief Financial Officer -50K $0.60 -$29.79K
    Green Julie Chief Human Resources Officer -50K $0.60 -$29.79K
    Lee Timothy Edward Chief Commercial Officer -50K $0.60 -$29.79K

    Earnings Calls

    Earnings Calls

    Latest earnings call: May 9, 2024 (Q1 2024)

    Add to watchlist

    Notifications